Updating results

Benralizumab for treating severe eosinophilic asthma (TA565)

Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults

Technology appraisal guidance Published March 2019 Last updated September 2019

Caesarean section

Everything NICE has said on caesarean section in an interactive flowchart

NICE Pathway Published November 2011 Last updated September 2019

The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

Advice on the use of the V.A.C. Veraflo Therapy system for infected wounds to aid local decision making

Medtech innovation briefing Published September 2019

Hypnotics (KTT6)

This document summarises the evidence base on hypnotics. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Asthma: medicines safety priorities (KTT5)

This document summarises the evidence base on asthma: medicines safety priorities. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Lipid-modifying drugs (KTT3)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)

This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published March 2019 Last updated September 2019

Shared decision making (KTT23)

This document summarises the evidence base on shared decision making. It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance.

Key therapeutic topic Published March 2019 Last updated September 2019

Chemotherapy dose standardisation (KTT22)

This document summarises the evidence base on chemotherapy dose standardisation. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2018 Last updated September 2019

Medicines optimisation in chronic pain (KTT21)

This document summarises the evidence base on medicines optimisation in chronic pain. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Safer insulin prescribing (KTT20)

This document summarises the evidence base on safer insulin prescribing. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)

This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Multimorbidity and polypharmacy (KTT18)

This document summarises the evidence base on multimorbidity and polypharmacy. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2017 Last updated September 2019

Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)

This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2016 Last updated September 2019

Antimicrobial stewardship: prescribing antibiotics (KTT9)

This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Antipsychotics in people living with dementia (KTT7)

This document summarises the evidence base on antipsychotics in people living with dementia. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)

This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants, including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published February 2016 Last updated September 2019

Wound care products (KTT14)

This document summarises the evidence base on wound care products. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)

This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance.

Key therapeutic topic Published January 2015 Last updated September 2019

Trauma

Everything NICE has said on assessing and managing trauma in an interactive flowchart

NICE Pathway Published February 2016 Last updated August 2019

Health of people in the criminal justice system

Everything NICE has said on managing the physical and mental health of people in prison, and the mental health of people in the criminal justice system

NICE Pathway Published November 2016 Last updated August 2019

Dapagliflozin with insulin for treating type 1 diabetes (TA597)

Evidence-based recommendations on dapagliflozin (Forxiga) with insulin for type 1 diabetes not controlled by insulin therapy alone in adults with a BMI of at

Technology appraisal guidance Published August 2019

Hypertension in adults: diagnosis and management (NG136)

This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

NICE guideline Published August 2019

Type 2 diabetes in adults: management (NG28)

This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

NICE guideline Published December 2015 Last updated August 2019

Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer

Technology appraisal guidance Published August 2019

Community pharmacies: promoting health and wellbeing

Everything NICE has said on how community pharmacies can promote health and wellbeing in an interactive flowchart

NICE Pathway Published August 2018 Last updated August 2019

Behaviour change

Everything NICE has said on changing people's health-related behaviours, including interventions aimed at over 16s, in an interactive flowchart

NICE Pathway Published January 2014 Last updated August 2019

Risankizumab for treating moderate to severe plaque psoriasis (TA596)

Evidence-based recommendations on risankizumab (Skyrizi) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published August 2019

Osteoporosis

Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

NICE Pathway Published August 2012 Last updated August 2019

Obesity

Everything NICE has said on preventing, identifying, assessing and managing obesity in an interactive flowchart

NICE Pathway Published October 2013 Last updated August 2019

Psoriasis

Everything NICE has said on psoriasis in an interactive flowchart

NICE Pathway Published October 2011 Last updated August 2019

Coexisting severe mental illness and substance misuse: assessment and management in healthcare settings

Everything NICE has said about assessing and managing coexisting severe mental illness and substance misuse in healthcare settings in an interactive flowchart

NICE Pathway Published September 2012 Last updated August 2019

Psychosis and schizophrenia

Everything NICE has said on recognising and managing psychosis and schizophrenia in children, young people and adults in an interactive flowchart

NICE Pathway Published February 2014 Last updated August 2019

Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

Evidence-based recommendations on dacomitinib (Vizimpro) for locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published August 2019

Brentuximab vedotin for untreated advanced Hodgkin lymphoma (terminated appraisal) (TA594)

NICE is unable to make a recommendation about the use in the NHS of brentuximab vedotin (Adcetris) for untreated advanced Hodgkin lymphoma in adults

Technology appraisal guidance Published August 2019

Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in adults

Technology appraisal guidance Published August 2019

Patisiran for treating hereditary transthyretin amyloidosis (HST10)

Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

Highly specialised technologies guidance Published August 2019

Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults

Interventional procedures guidance Published August 2019

Low-energy contact X-ray brachytherapy (the Papillon technique) for locally advanced rectal cancer (IPG659)

In January 2020, we withdrew this guidance to allow for further consultation with stakeholders.

Interventional procedures guidance Published August 2019

Blood and bone marrow cancers

Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

NICE Pathway Published December 2013 Last updated August 2019

Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

NICE guideline Published March 2018 Last updated August 2019

Alcohol interventions in secondary and further education (NG135)

This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.

NICE guideline Published August 2019

Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (TA592)

Evidence-based recommendations on cemiplimab (Libtayo) for treating locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC) in adults

Technology appraisal guidance Published August 2019

Skin cancer

Everything NICE has said on skin cancers, including melanoma, basal cell carcinoma and squamous cell carcinoma in an interactive flowchart

NICE Pathway Published March 2014 Last updated August 2019

PICO negative pressure wound dressings for closed surgical incisions (MTG43)

Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions

Medical technologies guidance Published May 2019 Last updated August 2019

Endo-SPONGE for colorectal anastomotic leakage (MIB188)

Advice on the use of Endo-SPONGE for colorectal anastomotic leakage to aid local decision making

Medtech innovation briefing Published August 2019

Mental health problems in people with learning disabilities

Mental health problems in people with learning disabilities

NICE Pathway Published September 2016 Last updated August 2019

Preterm labour and birth (NG25)

This guideline covers the care of women at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

NICE guideline Published November 2015 Last updated August 2019

Letermovir for preventing cytomegalovirus disease after a stem cell transplant (TA591)

Evidence-based recommendations on letermovir (Prevymis) for preventing cytomegalovirus (CMV) disease after a stem cell transplant in adults

Technology appraisal guidance Published July 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019